REVIEWED BY: Ms. Cairo
MY RECOMMENDATION: YES
AMAZON SUBSCRIPTION LINK: Deal Book
WEB ADDRESS: http://dealbook.blogs.nytimes.com/
BLOG DESCRIPTION: Daily news on mergers & acquisitions, I.P.O.'s, venture capital and more. Edited by Andrew Ross Sorkin
MY REVIEW: An excellent blog for investors and those interested in the financial future of the country... told from the New York Times' point of view!
Some sample paragraphs:
The long-awaited opinion in the Selectica case came out this week from Delaware Chancery Court. Vice Chancellor John W. Noble, in the 71-page opinion, validated the Selectica board’s decision to adopt a net operating loss poison pill and permit this pill to be set off after Versata intentionally crossed the pill’s threshold.
The facts of the case are frankly odd. They arose out of Versata’s acquisition of 5.2 percent of Selectica and Versata’s accompanying offer to acquire Selectica. (Both companies produce business software.) In response, Selectica adopted a low-threshold net operating loss poison pill that would be triggered when someone acquired 4.99 percent of its stock, rather than the more typical 15 percent trigger. Versata was exempted from this threshold to the extent that it did not subsequently acquire Selectica shares
-GE Disputes Incident in Paulson’s Book
-Citi Still Has Competive Pay, CFO Says
-Philip Morris to Buy Back $12 Billion in Shares
-Another View: Why Privacy Matters to the Swiss
-AIG Lines Up Underwriters for AIA Offering